NCT01594125 - Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2015

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Nintedanib high dose

twice daily oral dosing

DRUG

Nintedanib low dose

twice daily oral dosing

DRUG

Nintedanib medium dose

twice daily oral dosing

DRUG

Nintedanib medium dose

twice daily oral dosing

DRUG

Nintedanib high dose

twice daily oral dosing

Trial Locations (5)

1199.120.001 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo

1199.120.005 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

1199.120.002 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba

1199.120.003 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1199.120.004 Boehringer Ingelheim Investigational Site, Saga, Saga